Psychedelic therapeutics redesigned
Terran Biosciences is a biotech platform company developing transformative therapeutics for patients with neurological and psychiatric diseases. The company holds one of the largest psychedelic patent portfolios in the industry, with over 150 patents and patent applications spanning novel forms of psilocybin, MDMA, LSD, DMT, and other compounds. Its pipeline includes TerXT (a novel prodrug combination for schizophrenia) and Phase 3 selective serotonin 2A receptor antagonists licensed from Sanofi. The company also received FDA clearance for NM-101, an AI-enabled cloud-based software platform for analyzing neuromelanin MRI scans. Founded in 2019 by Dr. Samuel Clark, MD, PhD.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountOct 2019
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
